“We are proud to partner with Mission Health Communities, a premier provider of senior care and skilled nursing services, with a large footprint across the Midwest,” said Eric Buffkin, President and CEO at etectRx. “This partnership is set to enhance the standards of incontinence care at two of Mission Health’s communities with the potential to expand broader to all of their Midwest locations.”

As a mission-driven organization dedicated to enhancing the quality of life for residents, Mission Health continually seeks innovative solutions that improve care and operational efficiency. 

Mission Health Communities Enhances Resident Care Through eBrief Early Adopter Program.

UF Innovate | The Hub resident company etectRx, Inc., is partnering with Trilogy Health to pilot its latest technology, designed to assist caregivers and older adults in managing urinary incontinence. Eric Buffkin, CEO of etectRx, and Trilogy Health’s Executive Director, Holly Snyder, join Mary Furlong & Associates’ podcast to discuss how this innovative solution can prevent falls during the night and support staffing.

In this week’s Tech Tuesday for WCJB TV20, UF Innovate’s Melanie Morón interviews Eric Buffkin, CEO of UF Innovate | Accelerate resident company etectRx as he explains the company’s newest partnership with the Village, a senior care facility in Gainesville.

The partnership will help the company test their new incontinence-monitoring system in a real-world setting, aiming to bring enhanced care to seniors and improve staff efficiency.

In the United States, over half of senior care residents suffer from incontinence, a condition that presents considerable risks to aging individuals. This project aims to improve care in this area for an increasing elderly population while simultaneously relieving stress for staff at these facilities.

etectRx is a digital health sensor platform company offering a distinctive blend of intelligent software, services, and wireless sensor technology through its eBurst platform. This technology supports remote monitoring of multiple health conditions enhancing patient engagement and healthcare outcomes across stakeholders including patients, providers, and payers, by promoting accountability and awareness.

etectRX is a resident client of UF Innovate | Accelerate at The Hub in Gainesville, Florida.

etectRx announces record-breaking use of the ID-Cap System, utilized in University of Colorado’s HIV treatment study

The Quantification of Tenofovir Alafenamide Adherence and Exposure in Adults living with HIV (QUANTI-TAF) study evaluated drug concentrations in dried blood spots (DBS), in tandem with medication adherence measured by the ID-Cap System. The ID-Cap System’s remote patient monitoring (RPM) capabilities successfully enabled the QUANTI-TAF study to produce one of the largest and longest digital pill studies in HIV treatment history.

A seamless, end-to-end solution, the ID-Cap is the only ingestible sensor solution which allowed the study’s researchers to monitor, track, trend, report, and provide real-time, accurate data through etectRx’s core technology, eBurst. When nonadherence was detected by the ingestible sensor technology, University of Colorado researchers were able to intervene in a timely fashion to send real-time dosing reminders to patients’ smartphone apps.

QUANTI-TAF began in August 2020, and the last follow-up concluded in May 2023. A total of 84 participants were enrolled in the study for up to 4 months each, resulting in 8,910 expected ingestions over 9,049 days monitored, and a cumulative adherence rate of 95%. The QUANTI-TAF study showed consistently high acceptability of the ID-Cap System over time, as participants used it for up to approximately 112 days (4 months).

etectRX is a resident client of UF Innovate | Accelerate at The Hub in Gainesville, Florida.

ID-Cap System Powers Historic HIV Digital Pill Study.

Yet, despite the landmark FDA approval, digital pills have not exploded in pharma. Privacy and logistical concerns, especially while studying such applications for vulnerable populations, have lingered.

“At the end of the day, the patient has to be of a mindset that this medicine is helping,” says Eric Buffkin, CEO of UF startup and UF Innovate Accelerate client EtectRx, a digital health company. Without that, let alone digital therapy, even a traditional one will not succeed, he says.

Buffkin is a repeat entrepreneur and executive with more than 25 years of experience with tech and health-tech companies. Eric co-founded the company in 2009 with etectRx’s Senior Scientific Advisor, Neil Euliano. Most recently, Buffkin served as senior vice president of development and technical operations at etectRx.

“Eric holds expert knowledge of etectRx and its technology,” said Jeff Spafford, Chairman of etectRx. “Eric’s technical knowledge and industry expertise will be invaluable as we continue to commercialize the ID-Cap System.”

In related news

The MyTPill Study, which marks etectRx’s third NIH-sponsored study at Brigham and Women’s Hospital within the last two years, kicked off in March and will include 80 patients over the next four years. Patients will track their use of HIV medication by using the ID-Cap System for three months and an electronic pillbox for three months, with a short break in between. The research sites include leaders in HIV care at Fenway Health in Boston and at the University of Miami/Jackson Memorial HIV Clinic in Miami.

In related news